These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 510506)

  • 1. Effect of human seminal plasma on tumour-associated immunity in prostatic cancer. A preliminary report.
    Ablin RJ; Bhatti RA; Guinan PD; Bush IM
    Experientia; 1979 Nov; 35(11):1510-11. PubMed ID: 510506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of tumor-associated immunity by human seminal plasma and its possible role in the natural history of prostatic cancer.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur Urol; 1980; 6(4):225-8. PubMed ID: 7389776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of human seminal plasma on tumour-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    J Reprod Immunol; 1980 Feb; 1(5-6):337-45. PubMed ID: 7411523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of cytophilic antibody ('arming' factor) in the sera of patients with prostatic cancer by human seminal plasma.
    Bhatti RA; Ablin RJ; Zamora S; Totonchi E; Bush IM; Guinan PD
    Experientia; 1980 Mar; 36(3):349-50. PubMed ID: 7371799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur J Cancer (1965); 1980 Jun; 16(6):775-80. PubMed ID: 7408927
    [No Abstract]   [Full Text] [Related]  

  • 6. Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?
    Hoover P; Naz RK
    Int J Androl; 2012 Aug; 35(4):608-15. PubMed ID: 22321000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-mediated immunity in prostatic cancer and its diagnostic relevancy.
    Ablin RJ; Guinan PD; Bhatti RA
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):467-71. PubMed ID: 6190657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. II. Tissue- and disease-specificity of antitumour cell-mediated immunity.
    Bhatti RA; Ablin RJ; Guinan PD
    Eur J Cancer (1965); 1979 Jan; 15(1):133-6. PubMed ID: 421713
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. III. Inhibition of leucocyte migration.
    Ablin RJ; Marrow C; Guinan PD; Bruns GR; Sadoughi N; John T; Bush IM
    Urol Int; 1976; 31(6):444-58. PubMed ID: 1006873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Guinan PD
    Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor associated markers as organ-specific antigens of the human seminal plasma. II. Immunohistological studies].
    Dienst C; Uhlenbruck G; Heising J; Höller U; Dreessen C
    Z Hautkr; 1985 Jan; 60(1-2):157-64. PubMed ID: 2580399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of diethylstilboesterol diphosphate on tumour-assoiciated immunity in prostatic cancer. A preliminary report.
    Bhatti RA; Ablin RJ; Guinan PD; Totonchi E; Zamora S
    Experientia; 1978 Oct; 34(10):1364-5. PubMed ID: 738427
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormonal therapy and alterations of immunity in prostatic cancer.
    Ablin RJ
    Neoplasma; 1981; 28(3):345-50. PubMed ID: 7290262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia.
    Brannen GE; Coffey DS
    Cancer Treat Rep; 1977; 61(2):211-6. PubMed ID: 68825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulatory effects of estrogen on immunologic responsiveness. III. Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in prostatic cancer.
    Ablin RJ
    Am J Reprod Immunol (1980); 1981 Aug; 1(4):206-9. PubMed ID: 7337156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between immunosuppressive activity and immunoregulatory cytokines in seminal plasma: influence of sperm autoimmunity and seminal leukocytes.
    Ochsenkühn R; O'Connor AE; Hirst JJ; Gordon Baker HW; de Kretser DM; Hedger MP
    J Reprod Immunol; 2006 Aug; 71(1):57-74. PubMed ID: 16712948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: reactivity and specificity of responsiveness, and relationship to stage, grade and therapy.
    Bhatti RA; Ablin RJ; Guinan PD
    J Reticuloendothel Soc; 1979 Apr; 25(4):389-95. PubMed ID: 458777
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell-mediated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Nagubadi S; Zamora S; Guinan PD
    Clin Oncol; 1980 Sep; 6(3):253-64. PubMed ID: 7428203
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. IV. Leucocyte adherence inhibition.
    Ablin RJ; Bhatti RA; Guinan PD; Bruns GR
    Urol Int; 1976; 31(6):459-69. PubMed ID: 795128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects of oestrogen in prostatic cancer: update and further consideration.
    Ablin RJ
    Allergol Immunopathol (Madr); 1981; 9(1):63-70. PubMed ID: 7258047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.